FDA gives go-ahead to Proceed with STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma June 21, 2023
Supplemental BLA submitted to FDA Seeking Approval of CARVYKTI® for the Earlier Treatment of Patients with R/R Multiple Myeloma June 14, 2023
First-Ever Results from Dual Bispecific Combination Study Showing 96% ORR in Patients with R/R Multiple Myeloma June 6, 2023
Longer-Term Talquetamab Follow-Up Data Showing ORR of More Than 70% in Heavily Pretreated Patients with Multiple Myeloma presented June 6, 2023
Type II variation application to EMA submitted for a new indication for CARVYKTI in adult patients with relapsed and lenalidomide-refractory multiple myeloma May 31, 2023
ALX Oncology and Sanofi to Evaluate Evorpacept + SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma May 10, 2023
Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed R/R Multiple Myeloma April 27, 2023
Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Combinatorial IO Treatment Strategies April 6, 2023
First Patient dosed in the CaMMouflage Ph 1 Trial of CB-011 for the Treatment of R/R Multiple Myeloma April 6, 2023
Elranatamab Receives FDA and EMA Filing Acceptance with Submissions based on favorable MagnetisMM-3 trial results in patients with R/R multiple myeloma February 28, 2023
UK MHRA grants full Marketing Authorization to NEXPOVIO (selinexor), Velcade, and SVd combo for previously-treated multiple myeloma patients February 22, 2023
Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Ph 1b/2 Clinical Trial to the U.S. February 22, 2023
Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% vs SoC in Earlier Lines of Therapy for R/R Multiple Myeloma in Ph 3 KarMMa-3 Study February 22, 2023
42-Patient Interim Data, with 90% ORR in R/R Multiple Myeloma at NXC-201 Therapeutic Dose from Ph 1 Expansion Trial presented February 22, 2023
China NMPA Clears IND Application for Ph 1/2 Trial of FasTCAR-T GC012F for Treatment of R/R Multiple Myeloma February 22, 2023
FDA Clears IND Application for Ph 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of R/R Multiple Myeloma February 22, 2023
Kite And Arcellx Close Agreement To Co-Develop And Co-Commercialize Late-Stage Clinical CART-DdBCMA In Multiple Myeloma February 8, 2023
Ph 3 CARTITUDE-4 Study of CARVYKTI® (cilta-cel) meets Primary Endpoint in Patients with R/R Multiple Myeloma February 1, 2023
Data from Ph 1 UNIVERSAL Study of ALLO-715 for the Treatment of R/R Multiple Myeloma published in Nature Medicine February 1, 2023
ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer January 4, 2023
